Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Retrophin Inc (RTRX)

Retrophin Inc (RTRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,238,011
  • Shares Outstanding, K 51,052
  • Annual Sales, $ 175,340 K
  • Annual Income, $ -146,430 K
  • 60-Month Beta 0.71
  • Price/Sales 7.09
  • Price/Cash Flow N/A
  • Price/Book 4.10
Trade RTRX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.70
  • Most Recent Earnings $-0.26 on 02/24/20
  • Latest Earnings Date 11/05/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.44
  • Number of Estimates 4
  • High Estimate -0.35
  • Low Estimate -0.59
  • Prior Year -0.70
  • Growth Rate Est. (year over year) +37.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.52 +24.23%
on 11/02/20
24.96 -2.84%
on 11/11/20
+2.36 (+10.78%)
since 10/16/20
3-Month
17.22 +40.82%
on 09/24/20
24.96 -2.84%
on 11/11/20
+5.82 (+31.58%)
since 08/18/20
52-Week
8.98 +170.04%
on 03/18/20
24.96 -2.84%
on 11/11/20
+11.23 (+86.32%)
since 11/18/19

Most Recent Stories

More News
Travere Therapeutics Announces Completion of Patient Enrollment in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis

Topline data from interim 36-week proteinuria endpoint on track for first quarter of 2021

RTRX : 24.25 (-0.45%)
TVTX : 5.85 (+2.27%)
Retrophin Announces Corporate Name Change to Travere Therapeutics, Inc.

New name reflects dedication to patient- inspired mission of identifying, developing and delivering life-changing rare disease therapies

RTRX : 24.25 (-0.45%)
Retrophin Completes Acquisition of Orphan Technologies

Addition of OT-58 strengthens pipeline of potential first-in-class therapies targeting rare diseases

RTRX : 24.25 (-0.45%)
Retrophin to Present at Upcoming Investor Conferences

SAN DIEGO, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Company management will present at the following upcoming virtual investor conferences in November and...

RTRX : 24.25 (-0.45%)
Retrophin Reports Third Quarter 2020 Financial Results

Pivotal DUPLEX Study of sparsentan in FSGS nears completion of enrollment; topline proteinuria data expected 1Q21

RTRX : 24.25 (-0.45%)
Retrophin Announces Agreement to Acquire Orphan Technologies

Agreement a dd s OT-58, a novel enzyme replacement therapy in Phase 1/2 development for the treatment of classical homocystinuria

RTRX : 24.25 (-0.45%)
Retrophin to Report Third Quarter 2020 Financial Results

SAN DIEGO, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report third quarter 2020 financial results on Thursday, November 5, 2020 after the close of the U.S....

RTRX : 24.25 (-0.45%)
Retrophin, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq: RTRX) today announced that on October 10, 2020, the Compensation Committee of its Board of Directors granted inducement equity grants...

RTRX : 24.25 (-0.45%)
Retrophin Announces Presentation of Abstracts at ASN Kidney Week 2020 Reimagined

SAN DIEGO, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that it will present new data from a post-hoc analysis examining the proportion of patients with focal segmental...

RTRX : 24.25 (-0.45%)
Retrophin Announces Enrollment of First 280 Patients in Pivotal Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy

Topline data from 36-week proteinuria endpoint anticipated in third quarter of 2021

RTRX : 24.25 (-0.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Retrophin is a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases for which there are currently no viable options for patients. The Company's approved products include Chenodal', Cholbam, and Thiola',...

See More

Key Turning Points

3rd Resistance Point N/A
2nd Resistance Point 25.04
1st Resistance Point 24.65
Last Price 24.25
1st Support Level 23.95
2nd Support Level 23.64
3rd Support Level N/A

See More

52-Week High 24.96
Last Price 24.25
Fibonacci 61.8% 18.86
Fibonacci 50% 16.97
Fibonacci 38.2% 15.08
52-Week Low 8.98

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar